IMMUNITYBIO, INC. Increase (Decrease) in Accounts Payable, Trade
IMMUNITYBIO, INC. (IBRX) reported Increase (Decrease) in Accounts Payable, Trade of $3.65 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableTrade · last filed 2026-08-04
- IMMUNITYBIO, INC. increase (decrease) in accounts payable, trade for the quarter ending 2026-06-30 was -$247.00K.
- IMMUNITYBIO, INC. increase (decrease) in accounts payable, trade for the quarter ending 2026-03-31 was $3.90M, a 39.42% decline year-over-year.
- IMMUNITYBIO, INC. increase (decrease) in accounts payable, trade for the quarter ending 2025-12-31 was $979.00K.
- IMMUNITYBIO, INC. increase (decrease) in accounts payable, trade for the quarter ending 2025-09-30 was -$1.39M.
- IMMUNITYBIO, INC. increase (decrease) in accounts payable, trade for fiscal 2025 was -$190.00K.
- IMMUNITYBIO, INC. increase (decrease) in accounts payable, trade for fiscal 2024 was -$3.17M.
- IMMUNITYBIO, INC. increase (decrease) in accounts payable, trade for fiscal 2023 was -$6.48M, a 180.95% decline from fiscal 2022.
- IMMUNITYBIO, INC. increase (decrease) in accounts payable, trade for fiscal 2022 was $8.00M.
| Period end | Increase (Decrease) in Accounts Payable, Trade 3 month | Increase (Decrease) in Accounts Payable, Trade 6 month | Increase (Decrease) in Accounts Payable, Trade 9 month | Increase (Decrease) in Accounts Payable, Trade 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$247.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $3.65M 10-Q · filed 2026-08-04 | $4.63M derived: sum of 3 quarters · filed 2026-08-04 | $3.24M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $3.90M 10-Q · filed 2026-05-07 | $4.88M derived: sum of 2 quarters · filed 2026-05-07 | $3.49M derived: sum of 3 quarters · filed 2026-05-07 | -$2.73M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $979.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$413.00K derived: sum of 2 quarters · filed 2026-02-23 | -$6.63M derived: sum of 3 quarters · filed 2026-08-04 | -$190.00K 10-K · filed 2026-02-23 |
| 2025-09-30 | -$1.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$7.61M derived: sum of 2 quarters · filed 2026-08-04 | -$1.17M 10-Q · filed 2025-11-05 | -$4.38M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$6.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $223.00K 10-Q · filed 2026-08-04 | -$2.99M derived: sum of 3 quarters · filed 2026-08-04 | -$11.91M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $6.44M 10-Q · filed 2026-05-07 | $3.23M derived: sum of 2 quarters · filed 2026-05-07 | -$5.70M derived: sum of 3 quarters · filed 2026-05-07 | -$1.04M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$3.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$12.14M derived: sum of 2 quarters · filed 2026-02-23 | -$7.48M derived: sum of 3 quarters · filed 2026-02-23 | -$3.17M 10-K · filed 2026-02-23 |
| 2024-09-30 | -$8.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$4.27M derived: sum of 2 quarters · filed 2025-11-05 | $47.00K 10-Q · filed 2025-11-05 | -$2.83M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $4.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $8.97M 10-Q · filed 2025-08-05 | $6.09M derived: sum of 3 quarters · filed 2026-02-23 | $3.36M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $4.31M 10-Q · filed 2025-05-12 | $1.44M derived: sum of 2 quarters · filed 2026-02-23 | -$1.29M derived: sum of 3 quarters · filed 2026-02-23 | -$2.83M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | -$2.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$5.61M derived: sum of 2 quarters · filed 2026-02-23 | -$7.14M derived: sum of 3 quarters · filed 2026-02-23 | -$6.48M 10-K · filed 2026-02-23 |
| 2023-09-30 | -$2.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$4.27M derived: sum of 2 quarters · filed 2024-11-12 | -$3.60M 10-Q · filed 2024-11-12 | -$3.16M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$869.00K 10-Q · filed 2024-08-12 | -$432.00K derived: sum of 3 quarters · filed 2025-03-03 | $596.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $668.00K 10-Q · filed 2024-05-09 | $1.10M derived: sum of 2 quarters · filed 2025-03-03 | $2.13M derived: sum of 3 quarters · filed 2025-03-03 | $7.87M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $437.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $1.47M derived: sum of 2 quarters · filed 2025-03-03 | $7.21M derived: sum of 3 quarters · filed 2025-03-03 | $8.00M 10-K · filed 2025-03-03 |
| 2022-09-30 | $1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $6.77M derived: sum of 2 quarters · filed 2023-11-09 | $7.56M 10-Q · filed 2023-11-09 | $4.02M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-06-30 | $5.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $6.54M 10-Q · filed 2023-08-08 | $2.99M derived: sum of 3 quarters · filed 2024-03-19 | $218.00K derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-03-31 | $795.00K 10-Q · filed 2023-05-11 | -$2.75M derived: sum of 2 quarters · filed 2024-03-19 | -$5.52M derived: sum of 3 quarters · filed 2024-03-19 | -$9.42M derived: sum of 4 quarters · filed 2024-03-19 |
| 2021-12-31 | -$3.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$6.32M derived: sum of 2 quarters · filed 2024-03-19 | -$10.21M derived: sum of 3 quarters · filed 2024-03-19 | -$3.72M 10-K · filed 2024-03-19 |
| 2021-09-30 | -$2.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$6.67M derived: sum of 2 quarters · filed 2022-11-09 | -$170.00K 10-Q · filed 2022-11-09 | -$4.88M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | -$3.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $2.60M 10-Q · filed 2022-08-08 | -$2.10M derived: sum of 3 quarters · filed 2023-03-01 | $2.88M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $6.50M 10-Q · filed 2022-05-10 | $1.79M derived: sum of 2 quarters · filed 2023-03-01 | $6.78M derived: sum of 3 quarters · filed 2023-03-01 | $10.79M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | -$4.71M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $283.00K derived: sum of 2 quarters · filed 2023-03-01 | $4.29M derived: sum of 3 quarters · filed 2023-03-01 | $2.57M 10-K · filed 2023-03-01 |
| 2020-09-30 | $4.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $9.00M derived: sum of 2 quarters · filed 2021-11-12 | $7.28M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $4.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $2.29M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$1.72M 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | $1.19M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |